Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Completed · Not applicable

Conditions studied: High Risk of Developing Lung Cancer

In brief

Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Key facts

Study ID

NCT01700257

Run by

National Jewish Health

People needed

1361

Starts

2012-05-01

Expected to finish

2020-12-07

Last updated by the study team

2020-12-31

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Smokers or former smokers
• At least 20 pack year history of smoking
• Ages 50 - 75

You may not qualify if…

• Had a CT scan of chest within last 24 months
• History of any cancer within 10 yrs (except skin cancer or cervical cancer)
• A serious illness that decreases life expectancy to less than 5 years
• Any current use of Oxygen
• Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion
• Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy

Where it is running

• National Jewish Health — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.